SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name: Alvimopan Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Substance/Mixture: Pharmaceutical

1.3 Details of the supplier of the safety data sheet

Company: MSD
117 16th Road
07033 Halfway house, Midrand, South Africa

Telephone: +27 11 655 3000
Telefax: 908-735-1496

E-mail address of person responsible for the SDS: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)
Not a hazardous substance or mixture.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)
Not a hazardous substance or mixture.

Additional Labelling
EUH210 Safety data sheet available on request.

2.3 Other hazards

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components
## SECTION 4: First aid measures

### 4.1 Description of first aid measures

**General advice**: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

**Protection of first-aiders**: No special precautions are necessary for first aid responders.

**If inhaled**: If inhaled, remove to fresh air. Get medical attention if symptoms occur.

**In case of skin contact**: Wash with water and soap. Get medical attention if symptoms occur.

**In case of eye contact**: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.

**If swallowed**: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

### 4.2 Most important symptoms and effects, both acute and delayed

**Risks**: Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.

### 4.3 Indication of any immediate medical attention and special treatment needed

**Treatment**: Treat symptomatically and supportively.

## SECTION 5: Firefighting measures

### 5.1 Extinguishing media

**Suitable extinguishing media**: Water spray

**Alcohol-resistant foam**

**Carbon dioxide (CO2)**

**Dry chemical**

**Unsuitable extinguishing media**: None known.
SAFETY DATA SHEET

Alvimopan Formulation

Version 1.10  Revision Date: 13.09.2019  SDS Number: 643704-00011  Date of last issue: 24.04.2019
Date of first issue: 02.05.2016

5.2 Special hazards arising from the substance or mixture
Specific hazards during firefighting: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides

5.3 Advice for firefighters
Special protective equipment for firefighters: Wear self-contained breathing apparatus for firefighting if necessary. Use personal protective equipment.

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures
Personal precautions: Follow safe handling advice and personal protective equipment recommendations.

6.2 Environmental precautions
Environmental precautions: Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up
Methods for cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections
See sections: 7, 8, 11, 12 and 13.
SAFETY DATA SHEET

Alvimopan Formulation

Version 1.10  Revision Date: 13.09.2019  SDS Number: 643704-00011  Date of last issue: 24.04.2019

Date of first issue: 02.05.2016

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures:
Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation:
Use only with adequate ventilation.

Advice on safe handling:
Do not breathe dust. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures:
If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers:
Keep in properly labelled containers. Store in accordance with the particular national regulations.

Advice on common storage:
Do not store with the following product types: Strong oxidizing agents.

7.3 Specific end use(s)

Specific use(s):
No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alvimopan</td>
<td>170098-38-1</td>
<td>TWA</td>
<td>10 µg/m3</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>100 µg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>

8.2 Exposure controls

Engineering measures:
Ensure adequate ventilation, especially in confined areas. Minimize workplace exposure concentrations. Apply measures to prevent dust explosions.
Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

**Personal protective equipment**

- **Eye protection**: Wear the following personal protective equipment: Safety goggles
- **Hand protection**: Chemical-resistant gloves
- **Remarks**: For prolonged or repeated contact use protective gloves. Wash hands before breaks and at the end of workday.
- **Skin and body protection**: Skin should be washed after contact.
- **Respiratory protection**: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Filter type: Particulates type (P)

**SECTION 9: Physical and chemical properties**

### 9.1 Information on basic physical and chemical properties

- **Appearance**: powder
- **Colour**: No data available
- **Odour**: No data available
- **Odour Threshold**: No data available
- **pH**: No data available
- **Melting point/freezing point**: No data available
- **Initial boiling point and boiling range**: No data available
- **Flash point**: Not applicable
- **Evaporation rate**: No data available
- **Flammability (solid, gas)**: May form explosive dust-air mixture during processing, handling or other means.
- **Upper explosion limit / Upper flammability limit**: No data available
- **Lower explosion limit / Lower flammability limit**: No data available
- **Vapour pressure**: No data available
- **Relative vapour density**: No data available
- **Density**: No data available
- **Solubility(ies)**
9.2 Other information

- **Flammability (liquids)**: No data available
- **Molecular weight**: No data available
- **Particle size**: No data available

**SECTION 10: Stability and reactivity**

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

- **Hazardous reactions**: May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.

10.4 Conditions to avoid

- **Conditions to avoid**: Heat, flames and sparks. Avoid dust formation.

10.5 Incompatible materials

- **Materials to avoid**: Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

**SECTION 11: Toxicological information**

11.1 Information on toxicological effects

- **Information on likely routes of exposure**: Inhalation, Skin contact
Ingestion
Eye contact

**Acute toxicity**
Not classified based on available information.

**Product:**
Acute oral toxicity : Acute toxicity estimate: > 2.000 mg/kg
Method: Calculation method

**Components:**
**Alvimopan:**
Acute oral toxicity : LD50 (Rat): > 500 mg/kg
LD50 (Mouse): > 4.000 mg/kg
Acute dermal toxicity : LD50 (Mouse): > 2.000 mg/kg
Acute toxicity (other routes of administration) : LD50 (Rat): > 20 mg/kg
Application Route: Intravenous
Remarks: No significant adverse effects were reported

**Skin corrosion/irritation**
Not classified based on available information.

**Components:**
**Alvimopan:**
Species : Rabbit
Result : Mild skin irritation

**Serious eye damage/eye irritation**
Not classified based on available information.

**Components:**
**Alvimopan:**
Species : Rabbit
Result : Mild eye irritation

**Respiratory or skin sensitisation**
**Skin sensitisation**
Not classified based on available information.

**Respiratory sensitisation**
Not classified based on available information.

**Components:**
**Alvimopan:**
Test Type : Maximisation Test
Exposure routes : Dermal
Result: negative

**Germ cell mutagenicity**
Not classified based on available information.

**Components:**

**Alvimopan:**

Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative
- Test Type: Chromosome aberration test in vitro
  - Result: negative
- Test Type: In vitro mammalian cell gene mutation test
  - Test system: mouse lymphoma cells
  - Result: negative

Genotoxicity in vivo:
- Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
  - Species: Mouse
  - Application Route: Oral
  - Result: negative

**Carcinogenicity**
Not classified based on available information.

**Components:**

**Alvimopan:**

Species: Rat
- Application Route: Oral
- Exposure time: 2 Years
- NOAEL: 500 mg/kg body weight
- Result: negative

Species: Mouse
- Application Route: Oral
- Exposure time: 2 Years
- LOAEL: 4,000 mg/kg body weight
- Result: positive
- Target Organs: Bone, Skin
- Remarks: Benign and malignant tumor(s)
  - Adverse effects were observed in females only.
  - There is no evidence that these findings are relevant to humans.

**Reproductive toxicity**
Not classified based on available information.

**Components:**

**Alvimopan:**

Effects on fertility:
- Test Type: Fertility/early embryonic development
SAFETY DATA SHEET

Alvimopan Formulation

Version 1.10  Revision Date: 13.09.2019  SDS Number: 643704-00011  Date of last issue: 24.04.2019  Date of first issue: 02.05.2016

Species: Rat
Application Route: Intravenous injection
Fertility: NOAEL: 5 mg/kg body weight
Result: No effects on fertility

Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Oral
Fertility: NOAEL: 200 mg/kg body weight
Result: No effects on fertility

Test Type: Fertility/early embryonic development
Species: Rabbit
Application Route: Intravenous
Fertility: NOAEL: 15 mg/kg body weight
Result: No effects on fertility

Effects on foetal development:

Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 100 mg/kg body weight

Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 200 mg/kg body weight
Result: Embryo-foetal toxicity

Test Type: Embryo-foetal development
Species: Rat
Application Route: Intravenous injection
Developmental Toxicity: NOAEL: 10 mg/kg body weight
Result: No significant adverse effects were reported

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Intravenous injection
Developmental Toxicity: NOAEL: 15 mg/kg body weight
Result: No significant adverse effects were reported

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
Not classified based on available information.

Repeated dose toxicity

Components:

Alvimopan:
Species: Mouse
NOAEL: 1000 mg/kg
Application Route: Oral
Exposure time: 13 Weeks
Remarks: No significant adverse effects were reported

Species: Dog
NOAEL: 1000 mg/kg
Application Route: Oral
Exposure time: 39 Weeks
Remarks: No significant adverse effects were reported

Species: Rat
NOAEL: 500 mg/kg
Application Route: Oral
Exposure time: 1 yr
Remarks: No significant adverse effects were reported

Species: Dog
NOAEL: 2 mg/kg
Application Route: Intravenous
Exposure time: 1 Months
Remarks: No significant adverse effects were reported

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Alvimopan:
Ingestion: Symptoms: stomach discomfort, Gastrointestinal disturbance, Nausea, Vomiting, Abdominal pain

SECTION 12: Ecological information

12.1 Toxicity

Components:

Alvimopan:
Toxicity to fish: LC50 (Pimephales promelas (fathead minnow)): > 17 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): > 17 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic plants: EC50 (Scenedesmus subspicatus): > 17 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

NOEC (Scenedesmus subspicatus): 17 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms:
EC50: > 920 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
NOEC: 920 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

12.2 Persistence and degradability

**Components:**

**Alvimopan:**
Biodegradability: Result: Not readily biodegradable.
Biodegradation: 4%
Exposure time: 28 d

12.3 Bioaccumulative potential

**Components:**

**Alvimopan:**
Partition coefficient: n-octanol/water: log Pow: 0.52

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Not relevant

12.6 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

**Product:** Dispose of in accordance with local regulations.
According to the European Waste Catalogue, Waste Codes are not product specific, but application specific.
Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

**Contaminated packaging:** Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.
SECTION 14: Transport information

14.1 UN number
Not regulated as a dangerous good

14.2 UN proper shipping name
Not regulated as a dangerous good

14.3 Transport hazard class(es)
Not regulated as a dangerous good

14.4 Packing group
Not regulated as a dangerous good

14.5 Environmental hazards
Not regulated as a dangerous good

14.6 Special precautions for user
Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code
Remarks: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture
The components of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements
H302 : Harmful if swallowed.

Full text of other abbreviations
Acute Tox. : Acute toxicity

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regula-
SAFETY DATA SHEET

Alvimopan Formulation

Version 1.10
Revision Date: 13.09.2019
SDS Number: 643704-00011
Date of last issue: 24.04.2019
Date of first issue: 02.05.2016

Further information
Sources of key data used to compile the Safety Data Sheet:

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

ZA / EN